Translating the 2021 ESC Heart Failure Guideline Recommendations in Daily Practice: Results from a Heart Failure Survey. A Scientific Statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC
European Journal of Heart Failure · 2025
DOI: 10.1002/ejhf.3444 ↗Kurz gefasst
Leitlinie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Ruxandra Christodorescu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department V Internal Medicine, University of Medicine and Pharmacy V. Babes Timisoara, Timisoara, Romania. Hauptthemen laut MEDLINE: Heart Failure, Cardiology, Practice Guidelines as Topic, Societies, Medical. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Real-world data show that guidelines are insufficiently implemented, and particularly guideline-directed medical therapies (GDMT) are underused in patients with heart failure and reduced ejection fraction (HFrEF) in clinical practice. The Council for Cardiology Practice and the Heart Failure Association of the European Society of Cardiology (ESC) developed a survey aiming to (i) evaluate the perspectives of the cardiology community on the 2021 ESC heart failure (HF) guidelines, (ii) pinpoint disparities in disease management, and (iii) propose strategies to enhance adherence to HF guidelines. Methods and results A 22-question survey regarding the diagnosis and treatment of HFrEF was delivered between March and June 2022. Of 457 physicians, 54% were general cardiologists, 19.4% were HF specialists, 18.9% other cardiac specialists, and 7.7% non-cardiac specialists. For diagnosis, 52.1% employed echocardiography and natriuretic peptides (NPs), 33.2% primarily used echocardiography, and 14.7% predominantly relied on NPs. The first drug class initiated in HFrEF was angiotensin-converting enzyme inhibitors/angiotensin receptor–neprilysin inhibitor (ACEi/ARNi) (91.2%), beta-blockers (BB) (73.8%), mineralocorticoid receptor antagonists (MRAs) (53.4%), and sodium–glucose cotransporter 2 (SGLT2) inhibitors (48.1%). The combination ACEi/ARNi + MRA+ BB was preferred by 39.3% of physicians, ACEi/ARNi + SGLT2 inhibitors + BB by 33.3%, and ACEi/ARNi + BB by 22.2%. The time required to initiate and optimize GDMT was estimated to be <1 month by 8.3%, 1–3 months by 52%, 3–6 months by 31.8%, and >6 months by 7.9%. Compared to general cardiologists, HF specialists/academic cardiologists reported lower estimated time-to-initiation, and more commonly preferred a parallel initiation of GDMT rather than a sequential approach.
Conclusion
Participants generally followed diagnostic and treatment guidelines, but variations in HFrEF management across care settings or HF specialties were noted. The survey may raise awareness and promote standardized HF care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department V Internal Medicine, University of Medicine and Pharmacy V. Babes Timisoara, Timisoara, Romania.
- Institute of Cardiology Research Centre, Timișoara, Romania.
- Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania.
- University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania.
- Department of Cardiology and Vascular Pathology, CH Saint Joseph and Saint Luc, Lyon, France.
- Department of Cardiology, Herlev-Gentofte University Hospital, Copenhagen, Denmark.
Zitieren
APA
Christodorescu, R., Geavlete, O., Ferrini, M., Kümler, T., Toutoutzas, K., Bayes-Genis, A., Seferovic, P., Metra, M., Chioncel, O., Rosano, G. M. C., & Savarese, G. (2025). Translating the 2021 ESC Heart Failure Guideline Recommendations in Daily Practice: Results from a Heart Failure Survey. A Scientific Statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3444
Vancouver
Christodorescu R, Geavlete O, Ferrini M, Kümler T, Toutoutzas K, Bayes-Genis A, et al. Translating the 2021 ESC Heart Failure Guideline Recommendations in Daily Practice: Results from a Heart Failure Survey. A Scientific Statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3444
BibTeX
@article{Christodorescu2025,
author = {Christodorescu, Ruxandra and Geavlete, Oliviana and Ferrini, Marc and Kümler, Thomas and Toutoutzas, Konstantinos and Bayes-Genis, Antoni and Seferovic, Petar and Metra, Marco and Chioncel, Ovidiu and Rosano, Giuseppe M C and Savarese, Gianluigi},
title = {Translating the 2021 ESC Heart Failure Guideline Recommendations in Daily Practice: Results from a Heart Failure Survey. A Scientific Statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC},
journal = {European Journal of Heart Failure},
year = {2025},
doi = {10.1002/ejhf.3444}
}
EUVIMED